Scottish surgical device manufacturer Mpathy Medical hopes to achieve sales of $5million in the United States.

The Glasgow company's two main products - Minitape and Restorelle - are both made from its patented Smartmesh which is used in the treatment of abdominal hernia, female pelvic floor reconstruction and pelvic drug delivery. The products, developed by company founder Dr James Browning, are already generating strong revenues in America.

Overall sales for 12 months to May 2009 will be in the region of $1.5m, though chief executive Ian Stevens expects the figure to increase to $5m by the end of 2009.

He said: "Sales in our first year of trading have been very encouraging, and the feedback we have had from more than 100 US surgeons so far will help to push sales of our products significantly over the coming year.

"Pelvic organ prolapse and incontinence are very common conditions affecting around 15 per cent of women over the age of 50. So the market for us is in the hundreds of thousands of surgeries in these two areas carried out each year in the United States.

"As awareness of these conditions has grown, so too has the medical knowledge needed to tackle these problems, and Mpathy's products are now being seen as the benchmark for these surgical procedures."

So far Mpathy is focusing sales primarily in the United States, but Stevens hopes to expand the 26 strong sales force to push into Canada.

The company's polypropylene-based surgical procedure products are manufactured in the west of Scotland for export to the US.

Smartmesh was awarded both European and US Food and Drug Administration approval last year for use in surgical procedures, though the company has no plans to expand into Europe in the near future.

Stevens added: "Our focus will remain in the United States as it represents the world's largest healthcare market, and is the most conducive environment for a small company with a new product but limited resources."

Dr Browning, an urogynaecologist, began developing the concept for Smartmesh in 2001 with around £2m in research and development support from Archangel Investment and the Scottish Enterprise Co-Investment Fund.